



Patent claims:

1. A process for the preparation of allysine acetal of the general formula (I):



comprising:

contacting a hydantoin of the general formula (II):



10 wherein in formulae (I) and (II) R represents (C<sub>1</sub>-C<sub>8</sub>) -alkyl, (C<sub>2</sub>-C<sub>4</sub>) -alkylene, (C<sub>6</sub>-C<sub>18</sub>) -aryl, (C<sub>7</sub>-C<sub>19</sub>) -aralkyl, or (C<sub>1</sub>-C<sub>8</sub>) -acyl,

15 with a hydantoinase and a D- or L-specific carbamoylase,

under conditions suitable for *in situ* racemisation of the hydantoin or of an N-carbamoyl amino acid.

*Sub A2*

2. The process of Claim 1, wherein the hydantoinase, a D- or L-specific carbamoylase, or an enzyme used in racemization is used in free form, in immobilized form, as a cell fraction or extract, or in a form enclosed in a cell.

5

3. The process of Claim 1, wherein the *in situ* racemization is spontaneous, enzyme-catalysed, or both.

*Sub A3*

4. The process according to Claim 1, wherein a total cell catalyst is used, and wherein said total cell catalyst is obtained from a cell that comprises a cloned gene coding for a hydantoin racemase, a hydantoinase and an L- or D-specific carbamoylase.

10

5. The process according to Claim 4, wherein said total cell catalyst comprises an L-specific carbamoylase.

15

6. The process according to Claim 4, wherein the total cell catalyst is a recombinant bacterium.

20

7. The process according to Claim 6, wherein said recombinant bacterium is *E. coli*.

*Sub A4*

8. The process according to Claim 1 wherein the reactions are carried out in an enzyme-membrane reactor.

25

9. The process according to Claim 1, wherein the reactions are carried out sequentially or continuously.

*Sub A5*

10. The process according to Claim 1, further comprising a metal salt.

30

11. A method for producing a pharmaceutical or a biologically active product using an acetal produced by the process of Claim 1.

*Add A6*